GlassScriptPhysician profile
Robert J Golub
NPI 1851395651
$11,168.44
in general payments reported to CMS, 2019-2025
40 companies · $1,594 in 2025
The $1,594 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $811 · 2021: $1,487 · 2022: $1,462 · 2023: $1,973 · 2024: $2,309 · 2025: $1,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,876.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $992.83 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $950.01 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $798.92 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $783.05 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $741.48 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $685.87 | 2019-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $636.32 | 2019-2025 | |
| Esperion Therapeutics, INC. | $604.70 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $468.42 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $452.81 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.14 | 2019-2025 | Jardiance |
| Abbott Laboratories | $449.71 | 2019-2024 | Jot Dx, Cardiomems |
| Sanofi-Aventis U.S. LLC | $368.81 | 2019-2024 | |
| Scpharmaceuticals INC. | $295.87 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $264.03 | 2019-2025 | Evkeeza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $262.15 | 2019-2025 | Onpattro, Amvuttra |
| Actelion Pharmaceuticals US, INC. | $233.36 | 2019-2025 | Opsumit, Uptravi |
| Heartflow, INC. | $186.80 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $169.61 | 2024 | Arcalyst |
| Boston Scientific Corporation | $138.31 | 2023-2024 | Watchman, Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $126.86 | 2023-2024 | Inpefa |
| Abiomed | $122.39 | 2024-2025 | Impella |
| Genzyme Corporation | $98.95 | 2019-2024 | |
| Daiichi Sankyo INC. | $97.86 | 2019-2024 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.78 | 2019 | |
| Impulse Dynamics (USA) INC. | $79.42 | 2022-2023 | Optimizer |
| Bridgebio Pharma, INC. | $74.03 | 2025 | Attruby |
| Bardy Diagnostics, INC. | $72.85 | 2020-2021 | |
| Medtronic, INC. | $69.87 | 2024-2025 | Linq II, Symplicity G3 |
| Lundbeck LLC | $65.58 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $55.50 | 2022-2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $54.36 | 2019-2020 | |
| Cvrx, INC. | $43.52 | 2023 | Barostim Neo System |
| Philips North America LLC | $38.43 | 2022 | |
| Biotronik INC. | $32.48 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.43 | 2025 | |
| Medicomp INC | $31.08 | 2024 | Telepatch Cardiac Monitor |
| Lantheus Medical Imaging, INC. | $22.99 | 2021 | |
| Itamar Medical INC | $17.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Golub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.